In November 2025, the Company’s board of directors appointed Steve Hoerter to serve as executive chairperson, to support the Company’s executive team with his perspective and commercialization experience, as the Company prepares for the start of a Phase 3 trial and begins pre-commercial activities. Mr. Hoerter joined the Company’s board of directors earlier this year, bringing more than 30 years of pharmaceutical commercialization and executive leadership experience, most recently as President and Chief Executive Officer of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024. Jim Cornelius also retired from the board as of October 31, 2025, after more than five years of valuable service.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- DraftKings, Flutter downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 11/4/2025, According to Top Analysts
- Buy Rating for MBX Biosciences Driven by Promising PEP Platform and Successful Phase II Trials
- MBX Biosciences initiated with a Buy at TD Cowen
- MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide